视网膜血管瘤肿瘤抑制因子(vHL)活性蛋白
Active Von Hippel Lindau Tumor Suppressor (vHL)
HRCA1; RCA1; VHL1; Von Hippel-Lindau Syndrome
- 编号UAPJ769Hu01
- 物种Homo sapiens (Human，人) 相同的名称，不同的物种。
- 缓冲液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性状冻干粉
- 纯度> 80%
- 等电点4.4
- 应用Cell culture; Activity Assays.
- 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 858 ¥ 2145 ¥ 4290 ¥ 12870 ¥ 32175
- 欲了解实际交易价格和更多情况，请与当地经销商联系!
-
产品包装(模拟)
-
产品包装(模拟)
-
Figure. SDS-PAGE
-
通过ISO 9001、ISO 13485质量体系认证
活性实验
Von Hippel Lindau Tumor Suppressor (vHL) is a key tumor suppressor that plays a critical role in regulating cellular responses to oxygen levels. Encoded by the VHL gene, this protein functions primarily as part of a multi-protein E3 ubiquitin ligase complex, which targets specific proteins for degradation via the ubiquitin-proteasome system. To test the effect of vHL on cell proliferation, 293T cells were seeded into triplicate wells of 96-well plates and allowed to attach, replaced with various concentrations of recombinant human vHL. After incubated for 72h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10 µl of CCK-8 solution was added to each well of the plate, then the absorbance at 450 nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37 ℃. Cell viability was assessed by CCK-8 assay after incubation with recombinant human vHL for 72h. The result was shown in Figure 1. It was obvious that vHL significantly decreased cell viability of 293T cells. The ED50 of recombinant human vHL is 1.607 μg/ml.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
储存
避免反复冻融。2-8°C不超过一个月，-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定，具体方法如下：在37°C孵育48小时，没有显著的降解或者沉淀产生。保质期内，在适当的条件下存储，损失率低于5%。
增值服务
相关产品
| 编号 | 适用物种：Homo sapiens (Human，人) | 应用(仅供研究使用，不用于临床诊断！) |
| UAPJ769Hu01 | 视网膜血管瘤肿瘤抑制因子(vHL)活性蛋白 | Cell culture; Activity Assays. |
| URPJ769Hu01 | 视网膜血管瘤肿瘤抑制因子(vHL)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
